Top

BY Ron Gilmore

Just as a driver’s night vision improves by simply cleaning the headlights, scientists at The University of Texas MD Anderson Cancer Center have discovered that removing an unwanted element from a protein known to suppress the immune system may eventually help clinicians better observe which cancer patients will benefit by treatment with immune checkpoint blockades.

Heng-Huan Lee, Ph.D., a postdoctoral fellow and Ying-Nai Wang,...

Glycans attach to the PD-L1 protein on tumors, making it hard to detect. MD Anderson researchers have found that purging glycans makes PD-L1 easier to find and accurately assess. Image courtesy of Cancer Cell.

BY Scott Merville

MD Anderson researchers will present clinical trial results of promising combination therapies for a variety of cancers at the 2019 American...

BY Clayton R. Boldt, Ph.D.

MD Anderson’s proteomics platform provides a valuable institutional resource, complete with state-of-the-art instruments and specialized expertise...

BY Clayton R. Boldt, Ph.D.

Despite a plethora of new and promising treatments available, lung cancer remains the leading cause of cancer death in the United States, and will claim more than 150,000 lives this year. November is Lung Cancer Awareness Month, a time to bring the disease into focus and educate people about prevention, screening and treatments that save lives.

MD Anderson’s Lung Cancer Moon Shot™ team is committed to making new, patient-guided...

Lauren Averett Byers, M.D. and Don Gibbons, M.D., Ph.D.,

BY Scott Merville

Lung cancer immunotherapy triggers a counterattack by a surface protein found on the tumors of some patients that stifles the immune system...

BY Scott Merville

MD Anderson researchers have uncovered a genetic condition that thwarts the most common immunotherapy used against lung cancer, opening new...

BY Ron Gilmore

A drug discovered and advanced by MD Anderson’s Institute for Applied Cancer Science (IACS) and the TRACTION platform inhibits a vital...

BY Laura Sussman

In a randomized, Phase II trial led by researchers at MD Anderson, adding the PARP inhibitor veliparib to a standard chemotherapy agent improved...

BY Clayton Boldt, Ph.D.

Increasing the dosage of a prescription smoking cessation medication by 1 milligram a day – from 2 to 3 milligrams – more than doubled abstinence...

BY Clayton Boldt, Ph.D.

Elevated levels of chronic stress hormones, such as those produced by psychological distress, may promote resistance to drugs commonly used...